Pharma promotion spend for oncology dropped by 10 percent compared to summer 2010, despite new product introductions, according to a new report by Cegedim Strategic Data. What contributed to the decline? What role did the off-patent Femara play in affecting the ranking of top manufacturers in terms of promotional spend? Use this report to compare your promotional spend, and find out how oncology drug manufacturers are allocating their promotional budget across marketing channels.
Novartis and Genentech make up half of marketing spend